Pfizer Inc.
NYSE:PFE
Strategic Combinations, Mergers / Acquisitions
Myovant Sciences And Pfizer Announce Collaboration To Develop And Commercialize Relugolix
Published: 12/28/2020 11:38 GMT
Pfizer Inc. (PFE) - Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health.
Myovant Sciences Ltd - Myovant to Receive an Upfront Payment of $650 Million.
Myovant Sciences Ltd - Deal Includes Potential Regulatory and Sales Milestones for a Total Payment of Up to $4.2 Billion.
Myovant Sciences - Pfizer Will Get Exclusive Option to Commercialize Relugolix in Oncology Outside U.S. & Canada, Excluding Certain Asian Countries.
Myovant - Co, Pfizer to Jointly Develop and Commercialize Orgovyx and Relugolix Combination Tablet and Share Profits and Expenses in U.S. and Canada.
Myovant Sciences Ltd - Co, Pfizer Will Begin Co-promoting Orgovyx for Advanced Prostate Cancer in Early 2021.
Myovant Sciences Ltd - Myovant to Receive an Upfront Payment of $650 Million.
Myovant Sciences Ltd - Deal Includes Potential Regulatory and Sales Milestones for a Total Payment of Up to $4.2 Billion.
Myovant Sciences - Pfizer Will Get Exclusive Option to Commercialize Relugolix in Oncology Outside U.S. & Canada, Excluding Certain Asian Countries.
Myovant - Co, Pfizer to Jointly Develop and Commercialize Orgovyx and Relugolix Combination Tablet and Share Profits and Expenses in U.S. and Canada.
Myovant Sciences Ltd - Co, Pfizer Will Begin Co-promoting Orgovyx for Advanced Prostate Cancer in Early 2021.